Boston Scientific Expands Board and Boosts Share Buybacks
TipRanks (Mon, 23-Feb 5:37 PM ET)
Boston Scientific elects Cathy Smith and Christophe Weber to Board of Directors
PRNewswire (Mon, 23-Feb 8:00 AM ET)
BTIG Reaffirms Their Buy Rating on Boston Scientific (BSX)
TipRanks (Fri, 20-Feb 12:06 PM ET)
Boston Scientific’s TheraSphere Trial in Japan Signals New Growth Path in Liver Cancer
TipRanks (Fri, 20-Feb 11:34 AM ET)
PRNewswire (Thu, 19-Feb 8:09 PM ET)
ClearBridge Appreciation ESG Strategy adds new stake in Arista Networks in Q4, exits Oracle
Seeking Alpha News (Thu, 19-Feb 2:30 PM ET)
Boston Scientific to participate in TD Cowen's 46th Annual Health Care Conference
PRNewswire (Fri, 13-Feb 8:00 AM ET)
Business Wire (Mon, 9-Feb 2:04 PM ET)
Business Wire (Fri, 6-Feb 4:54 PM ET)
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Boston Scientific trades on the NYSE stock market under the symbol BSX.
As of February 24, 2026, BSX stock price climbed to $75.51 with 5,694,299 million shares trading.
BSX has a beta of 0.96, meaning it tends to be less sensitive to market movements. BSX has a correlation of 0.26 to the broad based SPY ETF.
BSX has a market cap of $111.98 billion. This is considered a Large Cap stock.
Last quarter Boston Scientific reported $5 billion in Revenue and $.80 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.02.
In the last 3 years, BSX traded as high as $109.50 and as low as $46.20.
The top ETF exchange traded funds that BSX belongs to (by Net Assets): VTI, VOO, VUG, IVV, SPY.
BSX has underperformed the market in the last year with a return of -27.7%, while the SPY ETF gained +15.7%. In the last 3 month period, BSX fell short of the market, returning -22.1%, while SPY returned +4.5%. However, in the most recent 2 weeks BSX has outperformed the stock market by returning +1.9%, while SPY returned -1.0%.
BSX support price is $73.28 and resistance is $75.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BSX shares will trade within this expected range on the day.